Azenta Crescita futura

Future criteri di controllo 3/6

Azenta prevede che gli utili e i ricavi cresceranno rispettivamente di 93.3% e 6.4% all'anno. Si prevede che l'EPS crescerà di 89.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -0.3% in 3 anni.

Informazioni chiave

93.3%

Tasso di crescita degli utili

89.9%

Tasso di crescita dell'EPS

Life Sciences crescita degli utili	18.4%
Tasso di crescita dei ricavi	6.4%
Rendimento futuro del capitale proprio	-0.3%
Copertura analitica	Good
Ultimo aggiornamento	04 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:AZTA - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
9/30/2027	811	25	N/A	N/A	1
9/30/2026	756	2	28	98	4
9/30/2025	712	-23	3	73	6
9/30/2024	661	-163	-101	-61	6
6/30/2024	659	-156	41	76	N/A
3/31/2024	652	-152	55	91	N/A
12/31/2023	641	-17	32	71	N/A
9/30/2023	665	-13	-22	17	N/A
6/30/2023	630	-21	-56	-13	N/A
3/31/2023	597	-26	-500	-449	N/A
12/31/2022	594	-25	-581	-509	N/A
9/30/2022	555	-11	-543	-466	N/A
6/30/2022	555	-28	-530	-449	N/A
3/31/2022	551	-23	-59	16	N/A
12/31/2021	535	-29	66	122	N/A
9/30/2021	514	-29	97	150	N/A
6/30/2021	114	-69	130	175	N/A
3/31/2021	205	-53	112	156	N/A
12/31/2020	296	-37	10	56	N/A
9/30/2020	389	-26	-2	38	N/A
6/30/2020	850	41	-19	19	N/A
3/31/2020	834	28	-7	29	N/A
12/31/2019	812	16	80	110	N/A
9/30/2019	334	-61	67	91	N/A
6/30/2019	741	3	70	89	N/A
3/31/2019	710	7	56	73	N/A
12/31/2018	668	72	63	77	N/A
9/30/2018	632	68	61	74	N/A
6/30/2018	488	35	62	78	N/A
3/31/2018	498	47	N/A	76	N/A
12/31/2017	510	-2	N/A	81	N/A
9/30/2017	527	11	N/A	96	N/A
6/30/2017	669	56	N/A	85	N/A
3/31/2017	634	47	N/A	82	N/A
12/31/2016	600	-51	N/A	71	N/A
9/30/2016	434	-85	N/A	40	N/A
6/30/2016	549	-73	N/A	38	N/A
3/31/2016	546	-74	N/A	39	N/A
12/31/2015	550	12	N/A	28	N/A
9/30/2015	553	14	N/A	44	N/A
6/30/2015	529	8	N/A	35	N/A
3/31/2015	502	-3	N/A	23	N/A
12/31/2014	489	-3	N/A	48	N/A
9/30/2014	483	1	N/A	54	N/A
6/30/2014	471	3	N/A	65	N/A
3/31/2014	464	10	N/A	73	N/A
12/31/2013	448	5	N/A	58	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che AZTA diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Si prevede che AZTA diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede AZTA diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di AZTA ( 6.4% all'anno) crescerà più lentamente rispetto al mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di AZTA ( 6.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che AZTA non sarà più redditizia tra 3 anni.

Azenta Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 7.2% to US$58.25

Consensus EPS estimates fall by 29%

Forecast to breakeven in 2026

No longer forecast to breakeven

Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024

Consensus EPS estimates fall by 20%

Recent updates

Azenta, Inc. to Report Q4, 2024 Results on Nov 12, 2024

Azenta, Inc Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test

Azenta: Life Science Play Is Not Coming To Life

Azenta, Inc. Announces Management Changes

Price target decreased by 7.2% to US$58.25

Consensus EPS estimates fall by 29%

Forecast to breakeven in 2026

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Azenta, Inc. to Report Q3, 2024 Results on Aug 06, 2024

Azenta, Inc.'s (NASDAQ:AZTA) Shares May Have Run Too Fast Too Soon

Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024

Stephen Schwartz to Retire as CEO of Azenta, Inc

Azenta, Inc. to Report Q2, 2024 Results on May 08, 2024

Should You Investigate Azenta, Inc. (NASDAQ:AZTA) At US$52.18?

Now 20% overvalued

Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price

Consensus EPS estimates fall by 20%

New major risk - Revenue and earnings growth

Senior VP notifies of intention to sell stock

Consensus EPS estimates fall by 19%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Azenta, Inc. Announces the Launch of the BioArc Ultra

Price target increased by 9.9% to US$72.00

Azenta, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc

Subdued Growth No Barrier To Azenta, Inc.'s (NASDAQ:AZTA) Price

Azenta, Inc., Annual General Meeting, Jan 30, 2024

Key Executive notifies of intention to sell stock

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 20%

Azenta, Inc. Provides Earnings Guidance for the Full Year Fiscal 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Azenta, Inc. to Report Q4, 2023 Results on Nov 13, 2023

Is There An Opportunity With Azenta, Inc.'s (NASDAQ:AZTA) 31% Undervaluation?

Politan Capital Provides Information to the Shareholders

Consensus EPS estimates upgraded to US$0.39 loss

Azenta, Inc. Announces Chief Financial Officer Changes, Effective October 16, 2023

Politan Capital Management Engages in Discussions with Azenta

Politan Capital Management Engages in Discussions with Azenta

At US$50.66, Is It Time To Put Azenta, Inc. (NASDAQ:AZTA) On Your Watch List?

Now 23% undervalued

New minor risk - Insider selling

Insider recently sold US$407k worth of stock

Independent Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Azenta, Inc. Revises Revenue Guidance for the Full Year of 2023

Estimating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)

Consensus EPS estimates upgraded to US$0.49 loss

Azenta, Inc. to Report Q3, 2023 Results on Aug 08, 2023

Now 20% undervalued

Independent Chairman notifies of intention to sell stock

Is Azenta, Inc. (NASDAQ:AZTA) Potentially Undervalued?

Price target decreased by 13% to US$52.50

Forecast breakeven date pushed back to 2025

Consensus revenue estimates decrease by 11%

Revenue Downgrade: Here's What Analysts Forecast For Azenta, Inc. (NASDAQ:AZTA)

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Azenta, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q2, 2023 Results on May 09, 2023

Is Azenta, Inc. (NASDAQ:AZTA) Worth US$42.5 Based On Its Intrinsic Value?

Consensus EPS estimates fall by 48%

Price target decreased by 8.2% to US$64.60

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Azenta, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q1, 2023 Results on Feb 08, 2023

Azenta, Inc. (NasdaqGS:AZTA) acquired Ziath Ltd.